Before visiting, please review our current visitor policies and COVID-19 information.
ECOG-ACRIN EA2187
Trial Overview
Official Title
Testing the Combination of Pevonedistat With Chemotherapy For Bile Duct Cancer Of The Liver
Study Purpose
To determine if the study drug, pevonedistat alone or pevonedistat in combination with carboplatin and paclitaxel is more efficient in shrinking your cancer.
Diagnosis
Advanced intrahepatic cholangiocarcinoma that is no longer controlled prior chemotherapy.Eligibility
Advanced intrahepatic cholangiocarcinoma that is no longer controlled with the first chemotherapy you tried.
Patients must sign an approved informed consent and authorization permitting release of personal health information.
Intervention
Group 1: Patients will get pevonedistat alone.
Group 2: Patients will get pevonedistat as well as chemotherapy.
After patients finish the study treatment, the doctor will continue to follow the patient’s condition and watch for side effects quarterly for 3 years.
For more information, visit ClinicalTrials.gov